These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15794199)

  • 41. Healthcare resource utilization and costs among patients with rheumatoid arthritis on biologic therapies in Taiwan: A 1-year mirror-image study using a national claims database.
    Chen KC; Wu CH; Tang CH; Huang KC
    PLoS One; 2018; 13(7):e0200758. PubMed ID: 30020997
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey.
    Hamuryudan V; Direskeneli H; Ertenli I; Inanc M; Karaaslan Y; Oksel F; Ozbek S; Pay S; Terzioglu E; Balkan Tezer D; Hacibedel B; Akkoc N
    Clin Exp Rheumatol; 2016; 34(6):1033-1037. PubMed ID: 27749224
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The costs of rheumatoid arthritis.
    Allaire SH; Prashker MJ; Meenan RF
    Pharmacoeconomics; 1994 Dec; 6(6):513-22. PubMed ID: 10155281
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
    Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The case of tumour necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis: a budget impact analysis.
    Sørensen J; Andersen LS
    Pharmacoeconomics; 2005; 23(3):289-98. PubMed ID: 15836009
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.
    Joensuu JT; Aaltonen KJ; Aronen P; Sokka T; Puolakka K; Tuompo R; Korpela M; Vasala M; Ilva K; Nordström D; Blom M
    Rheumatology (Oxford); 2016 Oct; 55(10):1803-11. PubMed ID: 27354689
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of estimated medical costs among patients who are defined as having rheumatoid arthritis using three different standards.
    Ruof J; Hülsemann JL; Mittendorf T; Handelmann S; Aultman R; von der Schulenburg JM; Zeidler H; Merkesdal S
    Eur J Health Econ; 2004 Feb; 5(1):64-9. PubMed ID: 15452767
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study.
    Lajas C; Abasolo L; Bellajdel B; Hernández-García C; Carmona L; Vargas E; Lázaro P; Jover JA
    Arthritis Rheum; 2003 Feb; 49(1):64-70. PubMed ID: 12579595
    [TBL] [Abstract][Full Text] [Related]  

  • 51. International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.
    Rosery H; Bergemann R; Maxion-Bergemann S
    Pharmacoeconomics; 2005; 23(3):243-57. PubMed ID: 15836006
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Economic burden of long-term care of rheumatoid arthritis patients in Hungary.
    Horváth CZ; Sebestyén A; Österle A; Endrei D; Betlehem J; Oláh A; Imre L; Bagosi G; Boncz I
    Eur J Health Econ; 2014 May; 15 Suppl 1():S131-5. PubMed ID: 24832843
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights.
    Curtis JR; Chen L; Greenberg JD; Harrold L; Kilgore ML; Kremer JM; Solomon DH; Yun H
    Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):310-319. PubMed ID: 28028867
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Indirect cost assessment in patients with rheumatoid arthritis (RA): comparison of data from the health economic patient questionnaire HEQ-RA and insurance claims data.
    Merkesdal S; Ruof J; Huelsemann JL; Mittendorf T; Handelmann S; Mau W; Zeidler H
    Arthritis Rheum; 2005 Apr; 53(2):234-40. PubMed ID: 15818718
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.
    Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Yuan Y; Oster G
    Rheumatology (Oxford); 2008 Apr; 47(4):535-41. PubMed ID: 18356179
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.
    Bansback NJ; Regier DA; Ara R; Brennan A; Shojania K; Esdaile JM; Anis AH; Marra CA
    Drugs; 2005; 65(4):473-96. PubMed ID: 15733011
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis.
    Kobelt G; Lindgren P; Lindroth Y; Jacobson L; Eberhardt K
    Rheumatology (Oxford); 2005 Sep; 44(9):1169-75. PubMed ID: 15956093
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'.
    Hülsemann JL; Ruof J; Zeidler H; Mittendorf T
    Rheumatol Int; 2006 Jun; 26(8):704-11. PubMed ID: 16261384
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hidden cost of rheumatoid arthritis (RA): estimating cost of comorbid cardiovascular disease and depression among patients with RA.
    Joyce AT; Smith P; Khandker R; Melin JM; Singh A
    J Rheumatol; 2009 Apr; 36(4):743-52. PubMed ID: 19228658
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project).
    Hallert E; Husberg M; Jonsson D; Skogh T
    Rheumatology (Oxford); 2004 Nov; 43(11):1374-82. PubMed ID: 15280570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.